Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small

ADXN

Addex Convenes Annual General Meeting 2026

Addex AGM set; board elections and capital-structure changes loom for ADXN

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Addex Therapeutics announced its 2026 AGM for June 29, with a governance-heavy agenda including board re-elections and amendments to the Articles of Association to raise capital. The capital-band and conditional share capital increases imply potential new share issuance and dilution if a financing occurs, signaling near-term dilution risk. The event may move ADXN shares ahead of the meeting as investors assess funding prospects and governance signals.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Addex schedules 2026 AGM for June 29 in Geneva.</li><li>Agenda includes board re-elections, compensation, and capital-structure amendments.</li><li>Proposed increases to capital band and conditional share capital.</li><li>Company highlights Dipraglurant program, Indivior partnership, and Neurosterix stake.</li><li>Forward-looking statements and risks noted; no guaranteed offering outcomes.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Addex Therapeutics AG (ADXN): AGM and capital-structure amendments may signal potential equity issuance and dilution risk.</li><li>Indivior PLC (INDV): Partner in Addex programs; governance/news may indirectly influence funding strategy.</li><li>Neurosterix US Holdings LLC (N/A): Private spin-out holding stake; potential future collaborations or monetization.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 Category: Corporate Developments. Fits as governance and capital-structure changes at a public company with listed ADRs/SIX-listed shares; could affect equity issuance risk and valuation.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>AGM timing and outcomes could trigger a price move for ADXN.</li><li>Capital-band increases imply possible future equity issuance, dilutive risk.</li><li>Board and auditor re-elections may influence strategic direction and funding decisions.</li><li>No concrete financing details yet; reaction hinges on announcements at/after AGM.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>AGM date/time: June 29, 2026, 11:00 CEST, Geneva.</li><li>Agenda includes approval of annual reports, compensation, and result appropriation.</li><li>Amendments to Articles: increase of capital band and conditional share capital.</li><li>Re-elections: Lawton (Chair), Hill, Dyer, Mills, Nunn, Manke.</li><li>Indivior collaboration and Dipraglurant program are highlighted in the description.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Near-term ADXN could drift on AGM news and potential dilution, with clarity on a financing plan needed.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - <a href="https://www.globenewswire.com/Tracker?data=_bOupRfopgVCKJ-cnysu1eECft6Idv0vbzV6G24dfOuTBf7BgDjR53e8acvVemoKiG0jHrX_bJPVrv8dzTPiZzjc7XYaZ81dAY5Zw26FJN52z5mKw36sHT6oM2gGIjxk" rel="nofollow" target="_blank">Addex Therapeutics</a> (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1.   Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2025 2.   Consultative vote on the Compensation Report for the business year 2025 3.   Appropriation of the results 4.   Discharge of the members of the Board of Directors and of the Executive Management 5.   Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors 5.1.    Re-election of Vincent Lawton as member and Chairman of the Board of Directors 5.2.    Re-election of Raymond Hill as member of the Board of Directors 5.3.    Re-election of Timothy Dyer as member of the Board of Directors 5.4.    Re-election of Roger Mills as member of the Board of Directors 5.5.    Re-election of Jake Nunn as member of the Board of Directors 5.6.    Re-election of Isaac Manke as member of the Board of Directors 6.   Re-elections of the members of the Compensation Committee 6.1.    Re-election of Vincent Lawton as member of the Compensation Committee 6.2.    Re-election of Raymond Hill as member of the Compensation Committee 7.   Re-election of the Auditor 8.   Re-election of the Independent Voting Rights Representative 9.   Amendments to the Articles of Association 9.1.    Increase of the capital band (article 3b of the Articles of Association) 9.2.    Increase of the conditional share capital (article 3c of the Articles of Association) 10.   Approval of the compensation of the members of the Board of Directors and of the Executive Management 10.1.     Compensation of the members of the Board of Directors 10.2.     Compensation of the members of the Executive Management 11.   Miscellaneous The full invitation to the AGM 2026 may be found in the General Meetings section of the Company's website <a href="https://www.globenewswire.com/Tracker?data=pn48BACNuB11VZi5-rTdKGVeCd0UPRxbXq4rw15W3QfeXrKgqs95y3rJXh8ZgMe_sBD4dZ2WuNSu9YtYZofAg-kxWQQ4rensMeayUHeUqGdw4v9CYkCGPKircb40aPjUBy_-m_9EDsTgIBaBI1jkaw==" rel="nofollow" target="_blank">here</a>. About Addex Therapeutics: <a href="https://www.globenewswire.com/Tracker?data=_bOupRfopgVCKJ-cnysu1eECft6Idv0vbzV6G24dfOsNaf-6bPRtk5ao-nukauWnJQH1xSEl_otRagxyRUK_4p616gI5ztZS0E69_2cM_kQ=" rel="nofollow" target="_blank">Addex Therapeutics</a> is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.   Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=VRjeXQd0RXjLOnRbEVcEZNZqPHum9bZBBDvFUuGnEhQEneo1ehO0dfPmV6Xw78gSb0CBbmesRscXL9OAn3psg8ARYID-FHDpsRFQIzM3wfHYtMocu1kxmAh7eR3fbaUY" rel="nofollow" target="_blank">www.addextherapeutics.com</a>.     Contacts:  <table style="border-collapse: collapse; border-collapse:collapse ;"><tr><td style="width:264px;;text-align: justify ; vertical-align: middle; vertical-align: top ; text-align: justify ; vertical-align: middle; "> Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  <a href="mailto:PR@addextherapeutics.com" rel="nofollow" target="_blank">PR@addextherapeutics.com</a> </td><td style="width:237px;;text-align: justify ; vertical-align: middle; vertical-align: top ; text-align: justify ; vertical-align: middle; ">Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  <a href="mailto:msinclair@halsin.com" rel="nofollow" target="_blank">msinclair@halsin.com</a> </td></tr></table> Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management&#39;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.  <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE4NjAxNCM0MDI0MDQwMzgjMjAwMjU4Ng=="></img> <img alt="" src="https://ml-eu.globenewswire.com/media/NzNhMjI2ZjMtMjQ4YS00NzYzLTlhOTYtNTRhMTQwYjc4YTMxLTEwMTQxNTktMjAyNi0wNi0wNS1lbg==/tiny/Addex-Therapeutics.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e6c12443-4244-46f9-909c-5ab241bbea41"><img src="https://ml-eu.globenewswire.com/media/e6c12443-4244-46f9-909c-5ab241bbea41/small/logo-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a>

Addex Therapeutics announced its 2026 AGM for June 29, with a governance-heavy agenda including board re-elections and amendments to the Articles of Association to raise capital. The capital-band and conditional share capital increases imply potential new share issuance and dilution if a financing occurs, signaling near-term dilution risk. The event may move ADXN shares ahead of the meeting as investors assess funding prospects and governance signals.

Addex Convenes Annual General Meeting 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News